EpiVax is pleased to announce our participation with the first HCP Workshop to take place May 15-16, 2014 in Dubrovnik, Croatia. EpiVax will be presenting their approch to assessing the immunogenic potential of host cell proteins using a proprietary in-silico tool, CHOPPI. See slides below.

The CHOPPI project is a collaboration between Dartmouth College, EpiVax, Inc. and the Institute for Immunology and Informatics (iCubed), and is driven by the EpiMatrix T cell epitope predictor developed by EpiVax.

Main Topics at the Meeting:

  • Screening and Assessing HCP Rare Reagents
  • Selecting Appropriate HCP assays for Early vs. Late Stage Development
  • Assessment of Various Technologies
  • Overcoming Common Analytical Development Hurdles
  • Update on USP General Chapter on HCP Assays
  • Impact of HCP Immune Responses in Humans

Over 15 Case Studies including:

  • Demonstration of antibody coverage. Alternatives to Western Blot
  • Characterization of new HCP reagents for Chinese Hamster Ovary Cells by High-Throughput Simple Western Technology
  • Measurement and Determination of Host Cell Proteins; What Methods to Use and When?
  • Strategies for the Replacement of the Host Cell Protein Immunoassay with “as good as or better” assay
  • Factors Leading to Sample Dilution Dependence
  • Identification of an antibody-bound HCP and the impact to Process Development
  • Assessing Immunogenicity Risk from Host Cell Proteins in Biotherapeutic Development
Dubrovnik HCP CHOPPI

EpiVax Presenting Host Cell Protein Immunogenicity Prediction Tool (CHOPPI) in Dubrovnik